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Abstract
Objectives To assess cost- effectiveness of enhanced 
recovery pathways following total hip and knee 
arthroplasties. Secondary objectives were to report on 
quality of studies and identify research gaps for future 
work.
Design Systematic review of cost–utility analyses.
Data sources Ovid MEDLINE, Embase, the National Health 
Service Economic Evaluations Database and EconLit, 
January 2000 to August 2019.
Eligibility criteria English- language peer- reviewed 
cost–utility analyses of enhanced recovery pathways, or 
components of one, compared with usual care, in patients 
having total hip or knee arthroplasties for osteoarthritis.
Data extraction and synthesis Data extracted by 
three reviewers with disagreements resolved by a 
fourth. Study quality assessed using the Consensus on 
Health Economic Criteria list, the International Society 
for Pharmacoeconomics and Outcomes Research and 
Assessment of the Validation Status of Health- Economic 
decision models tools; for trial- based studies the Cochrane 
Collaboration’s tool to assess risk of bias. No quantitative 
synthesis was undertaken.
Results We identified 17 studies: five trial- based and 
12 model- based studies. Two analyses evaluated entire 
enhanced recovery pathways and reported them to be 
cost- effective compared with usual care. Ten pathway 
components were more effective and cost- saving 
compared with usual care, three were cost- effective, and 
two were not cost- effective. We had concerns around risk 
of bias for all included studies, particularly regarding the 
short time horizon of the trials and lack of reporting of 
model validation.
Conclusions Consistent results supported enhanced 
recovery pathways as a whole, prophylactic systemic 
antibiotics, antibiotic- impregnated cement and 
conventional ventilation for infection prevention. No other 
interventions were subject of more than one study. We 
found ample scope for future cost- effectiveness studies, 
particularly analyses of entire recovery pathways and 
comparison of incremental changes within pathways. A 
key limitation is that standard practices have changed over 
the period covered by the included studies.
PROSPERO registration number CRD42017059473.
IntRODuCtIOn
Hip and knee arthroplasties are common 
procedures: around 1 million of each were 
performed in 2011 within Organisation for 
Economic Co- operation and Development 
countries,1 2 and rates continue to increase.3–6 
Enhanced recovery is a multimodal approach 
to reduce surgical morbidity and mortality. 
Recognising that factors other than surgical 
technique affect patient outcomes, Kehlet7 
considered how to optimise the preopera-
tive, intraoperative and postoperative phases 
of patient care. These principles have been 
further developed specifically within the 
context of hip and knee arthroplasty.8–15 
Common components of an enhanced 
recovery pathway for hip and knee arthro-
plasty are listed in box 1. A recent system-
atic review16 found that enhanced recovery 
after hip and knee arthroplasties reduced 
length of stay in hospital. The authors cited 
a study from New Zealand17 which found an 
enhanced recovery pathway to be cost saving, 
but the study did not include any data on 
cost- effectiveness.
Cost–utility analyses have become the 
preferred approach to inform decisions 
on healthcare resource allocation.18 19 In 
these, the effects of treatments are measured 
in quality- adjusted life years (QALY): the 
product of health- related quality of life 
(anchored at 0 for death and 1 for perfect 
health), and the time (in years) spent expe-
riencing that level of health. Incremental 
cost- effectiveness ratios (ICER) are used to 
Strengths and limitations of this study
 ► This systematic review of enhanced recovery path-
ways for hip and knee arthroplasties had a detailed 
search strategy, including entire pathways and their 
components.
 ► Appropriate tools were used to assess quality and 
validity of models, trials and economic evaluations.
 ► Conclusions were reliant on the availability, qual-
ity and validity of published studies into cost- 
effectiveness of hip and knee arthroplasty.
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Box 1 Suggested components of an enhanced recovery 
pathway for hip and knee arthroplasty patients, data from 
references cited in text.
Preoperative
 ► Education.
 ► Discharge planning.
 ► Multidisciplinary assessment.
 ► Neuromuscular electrical stimulation.
 ► Nutrition screening.
 ► Optimisation of comorbidities.
 ► Physiotherapy.
 ► Premedication (possibly including standardised analgesia and 
steroids).
 ► Pulsed electromagnetic fields.
Intraoperative
 ► Standardised intravenous fluids.
 ► Avoid unnecessary blood transfusion.
 ► Minimally invasive surgery.
 ► Reduce heat loss.
 ► Specified anaesthetic requirements, such as spinal anaesthesia.
 ► Local infiltration of anaesthesia.
 ► Tranexamic acid.
 ► Prophylactic antibiotics.
 ► Intravenous dexamethasone.
 ► Avoid unnecessary drains.
 ► Computer- assisted surgery.
Postoperative
 ► Analgesia.
 – Continuous neural block.
 – Standardised multimodal analgesia, scheduled and as required.
 – Reduce opioid use/avoid patient- controlled intravenous opioid 
analgesia.
 ► Scheduled antiemetic.
 ► Physical therapy starting on day of surgery.
 ► Avoid unnecessary blood transfusion.
 ► Oxygen administration.
 ► Avoid sleep disturbances.
 ► Early oral nutrition.
 ► Wound care.
 ► Thromboprophylaxis.
 ► Neuromuscular electrical stimulation.
 ► Aim for early discharge.
compare a treatment to a less effective alternative and a 
threshold value is used to determine whether it is cost- 
effective. Different countries have different thresholds 
for how much they are willing to pay per QALY gained.20
Systematic reviews of cost- effectiveness analyses have 
considered arthroplasty versus conservative manage-
ment,21 22 and specific components of enhanced recovery 
such as thromboprophylaxis.23–25 However, we are not 
aware of any systematic reviews investigating the cost- 
effectiveness of a complete enhanced recovery pathway, 
or of most of the components. Our aim was to assess 
the cost- effectiveness evidence of enhanced recovery for 
patients having hip and knee arthroplasty. Specifically, 
we were interested in studies of adults having total hip 
arthroplasty (THA) or total knee arthroplasty (TKA) for 
osteoarthritis, comparing an enhanced recovery pathway 
or components of one against usual care. Secondarily, we 
wanted to report study quality and identify research gaps 
for future work.
MEthODS
The complete methods are available in the published 
protocol,26 registered with the International 
Prospective Register of Systematic Reviews, number 
CRD42017059473.27 The selection of electronic databases 
and the search strategy were developed with an informa-
tion specialist and in line with the preferred reporting 
items for systematic reviews and meta- analyses.28 We 
searched Ovid MEDLINE, Embase, the National Health 
Service Economic Evaluations Database (via the Cochrane 
Library) and EconLit (via ProQuest) for English- language 
peer- reviewed papers published between 1 January 2000 
and 1 March 2017 which included a cost–utility analysis 
of an enhanced recovery pathway or components of one, 
compared with usual care in patients having hip or knee 
arthroplasties (the complete search strategy for each 
database is presented in online supplementary table A1). 
Additional publications meeting our inclusion criteria 
were identified from the reference lists of the included 
studies. We repeated our search in August 2019 to iden-
tify more recently published studies. Our target popula-
tion was adults having surgery for osteoarthritis. Studies 
exclusively concerning populations with other indica-
tions for surgery were excluded. We included studies 
with patients having different indications for surgery if 
the majority had osteoarthritis, or if the presented results 
allowed independent extraction of data for the subpop-
ulation with osteoarthritis. Given that osteoarthritis is an 
indication for 92% of hip and 96% of knee arthroplas-
ties,29 we assumed that studies not providing details of the 
indication for surgery were representative of a population 
with osteoarthritis and therefore included these studies. 
Evaluations of surgical technique or choice of implant 
were excluded.
Studies were independently screened based on their 
titles and abstracts by four reviewers (MGP, JM, LC and 
JL). Full texts were obtained for studies chosen for inclu-
sion by any reviewer. As an amendment to the protocol, 
evaluations of thromboprophylaxis were excluded at the 
full- text stage due to a recent comprehensive systematic 
review in that area.23 Data extraction was performed 
for remaining studies by three reviewers (MGP, JM and 
RJ), with disagreements resolved by a fourth reviewer 
(JL). The data extraction proforma is included in the 
published protocol.26
To assess the quality of studies, we completed the 
Consensus on Health Economic Criteria (CHEC) list30 
for each publication. For model- based studies, we also 
used the questionnaire produced by the International 
Society for Pharmacoeconomics and Outcomes Research 
(ISPOR),31 and the Assessment of the Validation Status of 
Health- Economic (AdViSHE) decision models tool.32 We 
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Figure 1 Flow diagram of studies included in this review and reasons for exclusion, modified from Moher et al.28 NHS EED, 
National Health Service Economic Evaluations Database; QALY, quality- adjusted life year.
added the Cochrane Collaboration’s tool33 to the orig-
inal protocol to assess risk of bias in trial- based studies, 
referring to the original reports of trial outcomes where 
necessary. We assessed the quality of the data sources 
used in the studies according to a prespecified hier-
archy of evidence tool (see online supplementary table 
A2).34 35 For each component of a study, a score of 1 
represented the use of the most appropriate data source, 
with increasing numbers representing progressively less 
appropriate sources.
The principal outcomes were a point estimate of cost- 
effectiveness in terms of incremental cost per QALY 
gained, and the probability of an intervention being cost- 
effective according to the willingness to pay threshold 
used by the authors of each study. We also examined 
whether an intervention could be cost- effective in a 
different country or setting than the original study. 
Hence, we assumed the studies to be generalisable and 
the ICERs to be comparable after conversion into 2016 
purchasing power parity international dollars (US PPP).36 
As the studies had different methodologies and looked at 
different combinations of components of the enhanced 
recovery pathway, no quantitative synthesis of the study 
results was attempted.
Patient and public involvement
No patient involved.
RESultS
Study selection
Our original search identified 11 060 publications, and 
one additional publication was found from other sources. 
We repeated the search in August 2019 and identified 
3903 additional studies. After excluding duplicates, we 
screened 8657 titles and abstracts. We excluded 8482 
papers based on their abstracts. For one study, we were 
unable to obtain the full text but it did not appear to be 
a cost- effectiveness study from the abstract. We therefore 
reviewed 174 full texts. We excluded 157 studies following 
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review of their full texts (reasons for exclusion given in 
figure 1) and included 17 papers in this review.37–53
Overview of included studies
Table 1 summarises the 17 included studies. Eight studies 
included both THA and TKA,37 38 40–43 45 49 five only 
THA44 46–48 53 and four only TKA.39 50–52 Two papers looked 
at an entire enhanced recovery pathway.37 38 We identified 
cost–utility evaluations of optimisation of comorbidities 
(specifically morbid obesity),39 measures to reduce allo-
genic blood transfusion,42–44 local infiltration of anaes-
thetic,45 prophylactic antibiotics and other infection 
prevention measures41 46–49 and physical therapy before40 
or after surgery.40 50–52 The final study53 concerned the 
optimal timing of follow- up which, although not included 
in our prior list of enhanced recovery interventions, we 
have included here as being allied to the pathway. Five 
studies were trial- based economic evaluations,37 38 40 45 51 
the remaining 12 being model- based. Eight studies were 
from Europe,37 38 40 45 47 49–51 seven from the USA39 41–44 46 52 
and two from Australia.48 53 Perspective, time horizon, 
discount rates and price year used in each study are 
reported in online supplementary table A3. The study 
perspective varied from only hospital costs42–44 46 48 52 53 
to a broader (societal) cost perspective.37–41 49 50 Types 
of costs captured in each study are reported in online 
supplementary table A4. Of the seven studies eliciting 
utilities, QALYs were informed by utility values based on 
the EQ- 5D- 3L instrument in six studies37 40 45 50 52 54 and on 
the 15D instrument in one study (online supplementary 
table A5).51
Assessment of study and reporting quality
Using the CHEC list, the quality of the studies was gener-
ally good (figure 2A). Items raising more concerns were 
the short time horizons of the five trial- based studies 
(1 year)37 38 40 45 51 and three model- based studies (between 
6 weeks49 and 7 years53). Using the Cochrane Collabo-
ration’s tool (figure 2B) for the five trials37 54–57 studies 
were based on, the risk of bias was low for items such as 
incomplete outcome data and selective reporting but 
high or uncertain for the remainder. Four trial reports 
stated that the participants were allocated at random,54–57 
and the fifth was a before and after trial whereby patients 
were recruited consecutively from a waiting list.37 Larsen 
and colleagues54 discussed stratification, Kauppila and 
colleagues55 reported a computer- generated sequence 
and Villadsen and colleagues56 used sequentially 
numbered sealed opaque envelopes. The staff adminis-
tering the interventions were not blinded to allocation in 
any trial, and in three trials37 55 57 outcomes were assessed 
by researchers aware of the treatment allocation. Using 
the ISPOR questionnaire, the quality of the model- based 
studies was generally good (figure 2C). However, none 
of the model- based studies reported a detailed process 
for internal and external validation. Four studies42 44 50 52 
were based on previously published models.58–61 Of these, 
only Briggs and colleagues58 (the basis for Fusco and 
Turchetti’s model50) provided details of model validation. 
Some model- based studies excluded potentially important 
outcomes, for example, Cummins and colleagues46 did 
not include the possibility of requiring more than one 
revision surgery, and in Bolz and colleagues’ model53 
there was no reduction in utility associated with delayed 
revisions. Further limitations in model validation were 
highlighted with the AdViSHE tool (figure 2D).32
The hierarchy of evidence used in the studies is 
reported in online supplementary table A6. Three model- 
based studies42 44 46 scored poorly as they did not use 
randomised trial data to inform the clinical effective size 
of the interventions being analysed. Most studies did not 
cite a source for the assumption of the duration of treat-
ment effect beyond that observed in the primary source 
for clinical effect size. Four trial- based studies and one 
model- based study included assessments of utilities from 
patients using validated tools and scored highly in terms 
of quality of evidence.
Results of economic evaluation
The results of the included studies are summarised in 
table 2. Costs, QALYs and ICERs for each comparison 
performed in each study are listed in online supplemen-
tary table A7.
Whole recovery pathway
Two studies considered multiple components of the 
enhanced recovery pathway. The first study was an 
economic analysis of a randomised trial with 56 THA and 
31 TKA participants in Denmark.38 The pathway used in 
the treatment arm (‘accelerated care’) had no difference 
from the control group (‘conventional rehabilitation’) in 
terms of intraoperative management, analgesia, nausea 
control or bowel regulation. Differences in the treatment 
protocols between the two arms involved patient educa-
tion, nutrition, admission times, staffing and mobilisa-
tion (described in online supplementary table A8). The 
accelerated care pathway was the dominant strategy both 
overall and in the subgroup of THA patients (ie, less costly 
and more effective than the control group). For TKA 
patients, the authors found the accelerated care pathway 
to be cost- saving but less effective compared with the 
control group although not statistically significant. There 
was a cost saving of 618 075 Danish krone per QALY lost 
with accelerated care compared with conventional reha-
bilitation, which made it cost- effective (threshold of 160 
000 krone per QALY in Denmark).
The second study was an economic evaluation of a 
before and after trial with 98 THA and 62 TKA participants 
in the Netherlands.37 The intervention (‘Joint Recovery 
Programme’) consisted of a 20 min pre- assessment 
screening 6 weeks before the operation for physical assess-
ment and analysis of the home situation to aid discharge 
planning, patient education sessions 1–2 weeks before 
surgery, group rehabilitation sessions and supervision 
by physical therapists and nurses (online supplementary 
table A8). Patients in the ‘usual care’ group underwent 
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conventional physiotherapy for 1 hour/day and did not 
receive pre- assessment screening or information sessions, 
and discharge arrangements were addressed during 
admission to hospital. The joint recovery programme 
intervention was dominant for both hip and knee replace-
ment, resulting in a cost saving of US$1261 per patient 
for THA and US$3336 per patient for TKA, with no statis-
tically significant difference in effect. The probability that 
the joint recovery programme was the most cost- effective 
option was above 80% for THA and TKA for willingness 
to pay thresholds up to US$45 000.
Preoperative components
McLawhorn and colleagues39 used a Markov model to 
assess the cost- effectiveness of bariatric surgery 2 years 
before TKA for morbidly obese (body mass index≥35 kg/
m2) patients who were candidates for both operations due 
to end- stage knee osteoarthritis and failed non- operative 
weight- loss interventions. The strategy including bariatric 
surgery was cost- effective at the stated willingness to pay 
threshold of US$100 000 per QALY in 98.8% of probabi-
listic simulations.
Fernandes and colleagues40 conducted an economic 
evaluation alongside a trial of 8 weeks of supervised 
neuromuscular exercise in addition to an educational 
package prior to surgery. Their point estimate was that 
the intervention was dominant, with a saving of 132 euro 
and a benefit of 0.04 QALYs. It had an 84% probability of 
being cost- effective at a willingness to pay threshold of 40 
000 euro per QALY.
Courville and colleagues41 compared three strategies of 
screening for and treating Staphylococcus aureus colonisa-
tion to prevent deep surgical site infections for TKA and 
THA. They found that decolonisation of all preoperative 
patients with mupirocin, without testing for S. aureus, was 
the dominant strategy (cheaper and more effective) when 
compared with treating patients testing positive only for 
S. aureus, or no screening or decolonisation for S. aureus.
Intraoperative components
Strategies to reduce allogenic blood transfusions were 
collection of autologous blood prior to surgery,44 aseptic 
collection of wound drainage42 and use of aminocaproic 
acid or tranexamic acid to reduce bleeding.43 Autologous 
blood collection was found to be cost- effective at US$2750 
per QALY gained, whereas wound drainage collection was 
not, costing US$5.7 million per QALY gained. However, 
in the latter study, the only benefit of avoiding allogenic 
transfusion considered was a reduced risk of blood- borne 
virus infection.42 In contrast, Sonnenberg’s model for 
THA44 found a minimal effect from the risk of blood- 
borne virus infection in either costs or outcomes: 99.6% 
of the increase in QALYs was due to a reduced risk of 
bacterial infection. When the risk of bacterial infection 
was removed from this model, the ICER increased to 
US$2.5 million per QALY gained. Use of tranexamic acid 
was more effective and cost- saving compared with either 
aminocaproic acid or not using a haemostatic agent.43
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Figure 2 Assessments of study quality based on tools from (A) Consensus on Health Economic Criteria,30 (B) International 
Society for Pharmacoeconomics and Outcomes Research,31 (C) assessment of the validation status of Health- Economic 
decision models tool32 and (D) Cochrane Collaboration.33 Note that the study by Brunenberg and colleagues37 was a non- 
randomised before and after trial and we have included it in panel (D) for completeness.
Marques and colleagues conducted economic evalu-
ations45 alongside two randomised controlled trials of 
adding local wound infiltration with bupivacaine to usual 
anaesthetic care for THA and TKA.57 The infiltration of 
local anaesthetic was found to be dominant compared 
with standard anaesthesia in both THA and TKA patients.
Three studies used Markov models to investigate similar 
measures to reduce surgical site infection in the USA,46 
the UK47 and Australia.48 The dominant strategy in all 
the three included the use of antibiotic- impregnated 
cement. The two studies that looked at other factors47 48 
each found use of prophylactic systemic antibiotics to be 
dominant over non- use, and use of conventional ventila-
tion in operating theatres to be dominant over laminar 
airflow ventilation. Graves and colleagues47 considered 
the use of body exhaust suits and found them to be domi-
nated by strategies that did not include use of these suits. 
A fourth study investigated using single- use negative pres-
sure wound dressings to reduce surgical site infection.49 
This was found to be dominant compared with usual care.
Postoperative components
Fusco and Turchetti50 used a Markov model to evaluate a 
strategy of 10 face- to- face rehabilitation sessions followed 
by 10 telerehabilitation sessions after TKA, compared with 
20 face- to- face sessions. They found the strategy including 
telerehabilitation to be cost saving, and improved range 
of movement (knee flexion). However, they found no 
utility data for patients following a telerehabilitation 
programme so for their base case assumed it to be non- 
inferior to face- to- face rehabilitation. In a sensitivity anal-
ysis, if telerehabilitation conferred an improvement in 
quality of life of at least 2.5%, the strategy’s probability 
of being cost- effective was 1; if it led to a reduction in 
quality of life of at least 2.5%, the probability of being 
cost- effective was 0 (each at a willingness to pay threshold 
of 30 000 euros per QALY).
Kauppila and colleagues51 performed an economic 
evaluation of a 10- day outpatient rehabilitation course 
between 2 and 4 months after TKA which included 
clinical assessments, physical activity, sessions with a 
psychologist and lectures from an orthopaedic surgeon, 
nutritionist and social worker.55 They found that patients 
who completed this course had higher costs and slightly 
worse quality of life outcomes over 1 year of follow- up 
(though the difference was non- significant at the 5% 
level) compared with those receiving conventional ortho-
paedic care.
Smith and colleagues52 used a Markov model to investi-
gate a postoperative strategy combining telephonic health 
coaching and financial incentives to increase physical 
activity. The intervention increased costs by US$300 and 
was associated with an increase in utility of 0.005 QALYs. 
The point- estimate ICER was US$57 200 per QALY, with a 
70% probability of being cost- effective at a willingness to 
pay threshold of US$100 000 per QALY.
Bolz and colleagues53 compared three follow- up strat-
egies: two yearly routine follow- up; follow- up twice (at 
3 months, and between 1 and 2 years after surgery) or no 
follow- up. The model assumed that no revisions would 
be delayed in either strategy that included follow- up, and 
the outcomes for these two strategies were identical in 
each analysis. The no follow- up strategy was dominant 
for any assumed rate of delayed revision between 1% and 
50%.
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Table 2 Summary of findings from studies included in this analysis
Authors, country Population Strategy Cost- effective?
Enhanced recovery pathway
Brunenberg et al, The 
Netherlands37
THA and TKA Conventional care –
Joint Recovery Programme (pre- assessment and intensive rehabilitation) Yes, more effective and 
less costly
Larsen et al, 
Denmark38
THA Conventional care –
Accelerated perioperative care and rehabilitation Yes, more effective and 
less costly
TKA Conventional care –
Accelerated perioperative care and rehabilitation Yes, less effective but less 
costly
Preoperative
McLawhorn et al, 
USA39
Morbid obese 
TKA
Immediate TKA –
Bariatric surgery, followed by TKA 2 years later Yes
Fernandes et al, 
Denmark40
THA and TKA Educational package –
Supervised neuromuscular exercise in addition to educational package Yes, more effective and 
less costly
Courville et al, USA41 THA and TKA Standard infection prevention measures without Staphylococcus aureus 
screening or mupirocin decolonisation OR preoperative nasal screening 
for S. aureus followed by mupirocin treatment for patients with positive 
cultures
–
Empirical treatment of all preoperative patients with mupirocin Yes, more effective and 
less costly
Intraoperative
Jackson et al, USA42 THA and TKA Usual transfusion practice –
Postoperative erythrocyte recovery and transfusion No
Ramkumar et al, 
USA43
THA and TKA No pharmacologic haemostatic agent OR single- dose intravenous 
aminocaproic acid
–
Single- dose intravenous tranexamic acid Yes, more effective and 
less costly
Sonnenberg, USA44 THA Usual practice without autologous donation –
Autologous blood donation and transfusion Yes
Marques et al, UK45 THA and TKA Standard anaesthesia –
Intraoperative local anaesthetic wound infiltration administered before 
wound closure in addition to standard anaesthesia
Yes, more effective and 
less costly
Cummins et al, USA46 THA Conventional cement –
Antibiotic- impregnated bone cement Yes, more effective and 
less costly
Graves et al, UK§47 THA No systemic antibiotics, plain cement and conventional ventilation –
Systemic antibiotics, antibiotic- impregnated cement and conventional 
ventilation
Yes, more effective and 
less costly
Merollini et al, 
Australia48
THA No antibiotic prophylaxis OR antibiotic prophylaxis OR antibiotic 
prophylaxis and laminar airflow
–
Antibiotic prophylaxis and antibiotic- impregnated cement Yes, more effective and 
less costly
Nherera et al, UK49 THA and TKA Usual care –
Single- use negative pressure wound therapy dressings Yes, more effective and 
less costly
Postoperative
Fusco and Turchetti, 
Italy50
TKA 20 face- to- face rehabilitation sessions –
10 face- to- face rehabilitation sessions plus 10 telesessions Yes, same effectiveness 
but less costly
Continued
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Authors, country Population Strategy Cost- effective?
Kauppila et al, 
Finland51
TKA Conventional orthopaedic care –
Multidisciplinary biopsychosocial outpatient rehabilitation programme No
Smith et al, USA52 TKA Telephone calls conveying general health messages –
Telephonic health coaching and financial incentives to increase physical 
activity
Yes
Bolz et al, Australia53 THA 2- yearly routine follow- up OR follow- up at 3 months and 1 or 2 years –
No follow- up Yes, more effective and 
less costly
THA, total hip arthroplasty; TKA, total knee arthroplasty.
Table 2 Continued
Effects of standardising currencies and price years
Most studies showed one strategy to be dominant (ie, 
cheaper and more effective) over the others37 38 40 41 43 45–51 53 
and were therefore not affected by changes in currency 
or price year. When converted into 2016 US PPP, will-
ingness to pay thresholds ranged between US$22 112 
(Denmark) and US$100 000 (USA, online supplementary 
table A9). Autologous blood transfusion44 and bariatric 
surgery39 would be cost- effective across all willingness 
to pay thresholds identified in the review. The capture 
and replacement of red cells42 cost 7.8 million US PPP 
dollars per QALY gained and would not be cost- effective 
by any study’s thresholds. Telephonic health coaching 
and financial incentives to increase physical activity52 
were cost- effective at a willingness to pay of US$100 000 
per QALY but not with any lower threshold. Accelerated 
care pathway in TKA patients in Denmark38 would not be 
cost- effective in a US setting using a willingness to pay of 
US$100 000 per QALY.
DISCuSSIOn
Summary of evidence
Our objective was to assess the cost- effectiveness evidence 
of enhanced recovery following THA or TKA through 
a systematic collection of published cost–utility data. 
Previous systematic reviews considered effectiveness16 
and patient satisfaction,62 but we believe that this is the 
first systematic review assessing the cost- effectiveness of 
enhanced recovery for THA or TKA patients. We identi-
fied two cost–utility analyses of an entire pathway. This is 
consistent with reviews of cost- effectiveness of enhanced 
recovery programmes for other surgical sites,63–65 which 
have found few studies that reported the effect on 
quality of life and none presented the cost- effectiveness 
results using QALYs. Both studies that considered cost- 
effectiveness of an entire recovery pathway were trials in 
both TKA and THA patients.37 38 The enhanced recovery 
pathway was found to be associated with reduced costs for 
all patients and the incremental cost- effectiveness esti-
mate favoured the enhanced recovery protocol, with a 
high probability of being the most cost- effective option.
We identified 15 studies presenting cost–utility data 
for components of an enhanced recovery pathway. These 
studies covered only a few of the potential enhanced 
recovery pathway components and were conducted across 
different healthcare systems using different cost perspec-
tives. Three studies investigated overlapping strategies 
for reducing surgical infections supporting the use of 
prophylactic systemic antibiotics, antibiotic- impregnated 
cement and conventional ventilation.46–48 No other inter-
ventions were examined by more than one study. Scope to 
combine or generalise results is therefore limited.
The studies identified in this review were generally of 
good quality according to the CHEC list30 with a short 
time horizon identified as a key limitation in nine studies 
(between 6 weeks and 7 years). This is of significant 
concern as short time horizons will not capture or model 
the impact of the interventions on costs and benefits 
accruing over the long post- acute care period of interest. 
Furthermore, we also found that the large majority of 
studies did not consider ethical aspects and distributional 
implications of their findings. When the models were 
assessed against the ISPOR questionnaire,31 there were 
concerns about the lack of model validation work, poten-
tially questioning the reliability of 10 of the 12 studies 
identified. The trials were generally of good quality. One 
trial was a non- randomised before and after trial,37 and 
participants were not blinded to the intervention for post-
operative interventions in any of the studies. However, we 
concluded that the overall risk of bias among the studies 
appeared low.
limitations of this review
We may have missed relevant evidence by limiting our 
search to reports published in the English language and 
excluding studies that did not report QALYs. Cost–utility 
analyses enable comparison between different interven-
tions and are the preferred intelligence for healthcare 
allocation decisions.18 19 We therefore felt justified in 
limiting our review to studies reporting QALYs. We identi-
fied one study excluded due to not reporting QALYs that 
investigated a complete enhanced recovery pathway.66 In 
this study, the recovery pathway was found to be cost- saving 
and associated with statistically significant differences in 
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knee flexion and extension at 6 months. However, the 
clinical significance of these differences was not discussed 
and no health- related quality of life data were collected.66
The second limitation is that standard practices have 
changed during the period covered by the included 
studies. For example, many enhanced recovery techniques 
are now standard practice,8 and Nherera and colleagues49 
even included enhanced recovery pathway as usual care in 
their model. Furthermore, other practices in the included 
studies are now outdated. For example, patients in the 
control group of Brunenberg and colleagues’ trial had 
had an in- patient stay of 9.4 days,37 whereas by 2015 the 
mean length of stay in England was 4.9 days for TKA and 
5.4 days for THA8 and has further decreased since.67 Also, 
practices such as blood transfusion rates have changed 
greatly: the two studies included in this review assumed 
transfusion rates of 89%44 to 100%,42 whereas rates in 
2014 were 22% for THA and 18% for TKA patients,68 and 
rates of infection from blood transfusion are now lower 
than those used in the models.69
Research gaps for future work
Use of prophylactic systemic antibiotics and antibiotic- 
impregnated cement, and thromboprophylaxis23–25 
are the only measures investigated in more than one 
cost–utility analysis. There is therefore very wide scope 
for further investigation of components of enhanced 
recovery. Pathways have a ‘whole package’ benefit in 
excess of the sum of their parts and can be used to ensure 
dissemination of evidence- based practice and delivery of 
more consistent care.70–72 From this perspective, specific 
components within a pathway might be less important 
than the degree of compliance with a protocol. However, 
as the use of care pathways becomes more prevalent, 
optimising their components will be the next step in 
improving outcomes.
COnCluSIOnS
There is limited cost–utility evidence, either for an entire 
enhanced recovery pathway or for individual components 
of a pathway, for patients having THA or TKA. There are 
also concerns regarding the ability of short time horizons 
in trials in this area to capture relevant outcomes, and 
regarding a general lack of reporting of model valida-
tion. Our findings support the use of enhanced recovery 
pathways as a whole, prophylactic systemic antibiotics, 
antibiotic- impregnated cement and conventional ventila-
tion. No other interventions were assessed by more than 
one study. Those single studies supported use of empir-
ical preoperative S. aureus decolonisation of all patients 
with mupiricin, single- dose intravenous tranexamic acid, 
wound infiltration with local anaesthetic, single- use nega-
tive pressure wound therapy dressings, bariatric surgery 
for morbidly obese patients requiring TKA, use of telere-
habilitation and telephonic health coaching with finan-
cial incentives to increase physical activity. However, we 
were unable to conclude how transferable these findings 
would be into other healthcare systems. There is ample 
scope for future cost- effectiveness studies into enhanced 
recovery for THA and TKA patients. In particular, we 
recommend analysis of entire enhanced recovery path-
ways and comparison of incremental changes of compo-
nents within pathways rather than considering aspects of 
care in isolation.
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